CooperVision Inc said it hasdelayed its annual meeting to June 22 from May 14 to allow itsboard to review possible recapitalization options before themeeting.    CooperVision today reported first quarter net income of64.6 mln dlrs, after a 175.2 mln dlr pretax gain from the saleof its ophthalmic business to Johnson and Johnson &lt;JNJ> for 260mln dlrs in cash and a 17.9 mln dlr posttax charge from a debtrepurchase.  Sales were 94.4 mln dlrs.  A year earlier itearned 7,300,000 dlrs after a 120,000 dlr loss fromdiscontinued operations, on sales of 85.4 mln dlrs.    The company said an aggressive program of investmentspending to maintain or increase market shares its its two corebusinesses will accelerate sales growth this year but hold backincreases in operating income in the near future.    CooperVision said "Furthermore, until the entire net cashproceeds from the recent sales of several of our businesses areemployed to reduce indebtedness, make strategic acquisitionsand/or are otherwise employed in relation to a possiblerecapitalization of the company, recovery of net income will beheld back by the loss, particularly of the tax income, of the(ophthalmic) pharmaceutical business sold to Johnson andJohnson." Reuter&#3;